Table 4. TRAEs in SAS.

AEsAny grade	All patients, n (%)
Hypothyroidism	7 (20.6)	7 (20.6)	0 (0.0)
Arrhythmia	5 (14.7)	4 (11.8)	1 (2.9)
Atrial premature beats	2 (5.9)	2 (5.9)	0 (0.0)
Atrioventricular block	2 (5.9)	2 (5.9)	0 (0.0)
Atrial fibrillation	1 (2.9)	0 (0.0)	1 (2.9)
Immune-related pneumonitis	3 (8.8)	1 (2.9)	2 (5.9)
Abnormal hepatic function	2 (5.9)	2 (5.9)	0 (0.0)
Blood creatinine increased	2 (5.9)	2 (5.9)	0 (0.0)
Proteinuria	3 (8.8)	3 (8.8)	0 (0.0)
Fatigue	2 (5.9)	2 (5.9)	0 (0.0)
Hyperglycemia	2 (5.9)	2 (5.9)	0 (0.0)
Creatine kinase	2 (5.9)	2 (5.9)	0 (0.0)
Hypertension	2 (5.9)	2 (5.9)	0 (0.0)
Rash	1 (2.9)	1 (2.9)	0 (0.0)
Left ventricular ejection fraction decreased	1 (2.9)	1 (2.9)	0 (0.0)
Catheter-related infection	1 (2.9)	0 (0.0)	1 (2.9)
Any AE	18 (52.9)	14 (41.1)	4 (11.8)

TRAE, treatment-related adverse event; SAS, safety analysis set; AE, adverse event.